



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 233/54, 233/58, A61K 31/41	A1	(11) International Publication Number: WO 96/16041 (43) International Publication Date: 30 May 1996 (30.05.96)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) International Application Number: PCT/US95/16034 (22) International Filing Date: 22 November 1995 (22.11.95) (30) Priority Data: 08/344,282 22 November 1994 (22.11.94) US 08/485,427 7 June 1995 (07.06.95) US (71) Applicant: CLARION PHARMACEUTICALS INC. [US/US]; 585 Science Drive, Madison, WI 53711 (US). (72) Inventors: PALTAUF, Friedrich; St. Peter-Hauptstrasse 29B, A-8042 Graz (AT). HERMETTER, Albin; Sandgasse 23, A- 8042 Graz (AT). FRANZMAIR, Rudolf; Freistädter Strasse 430/5, A-4040 Linz (AT). (74) Agents: SCANLON, William, J. et al.; Foley & Lardner, 150 East Gilman Street, Madison, WI 53701-1497 (US). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> (81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </td> </tr> </table>			(21) International Application Number: PCT/US95/16034 (22) International Filing Date: 22 November 1995 (22.11.95) (30) Priority Data: 08/344,282 22 November 1994 (22.11.94) US 08/485,427 7 June 1995 (07.06.95) US (71) Applicant: CLARION PHARMACEUTICALS INC. [US/US]; 585 Science Drive, Madison, WI 53711 (US). (72) Inventors: PALTAUF, Friedrich; St. Peter-Hauptstrasse 29B, A-8042 Graz (AT). HERMETTER, Albin; Sandgasse 23, A- 8042 Graz (AT). FRANZMAIR, Rudolf; Freistädter Strasse 430/5, A-4040 Linz (AT). (74) Agents: SCANLON, William, J. et al.; Foley & Lardner, 150 East Gilman Street, Madison, WI 53701-1497 (US).	(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(21) International Application Number: PCT/US95/16034 (22) International Filing Date: 22 November 1995 (22.11.95) (30) Priority Data: 08/344,282 22 November 1994 (22.11.94) US 08/485,427 7 June 1995 (07.06.95) US (71) Applicant: CLARION PHARMACEUTICALS INC. [US/US]; 585 Science Drive, Madison, WI 53711 (US). (72) Inventors: PALTAUF, Friedrich; St. Peter-Hauptstrasse 29B, A-8042 Graz (AT). HERMETTER, Albin; Sandgasse 23, A- 8042 Graz (AT). FRANZMAIR, Rudolf; Freistädter Strasse 430/5, A-4040 Linz (AT). (74) Agents: SCANLON, William, J. et al.; Foley & Lardner, 150 East Gilman Street, Madison, WI 53701-1497 (US).	(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(54) Title: HETEROARYL-SUBSTITUTED DEOXY GLYCERO-PHOSPHOETHANOLAMINES				
(57) Abstract Therapeutically active, heteroaryl-substituted deoxy glycerophosphoethanolamines are disclosed having general formula (I) wherein one of X, Y or Z is a fatty ether substituent, one is a heteroaryl ring substituent with 1 - 4 nitrogens as the only heteroatoms, one of which is bonded to a carbon of the glyceryl backbone, and one is a phosphoethanolamine substituent substituted at the nitrogen, provided that each of X, Y and Z is a different substituent. Also disclosed are intermediates in processes for making compounds of formula (I). The intermediates are represented by a modification of general formula (I) in which the phosphoethanolamine substituent is replaced with an hydroxyl group. The invention encompasses all optical isomers and stereoisomers of the compounds of formula (I) and the intermediates and salts of these compounds, including the isomers. The therapeutically active compounds of the invention have anti-tumor, anti-psoriatic and anti-inflammatory activities. The invention entails pharmaceutical compositions comprising the therapeutically active compounds and methods of using the therapeutically active compounds to treat cancerous tumors, psoriasis and inflammation. $\begin{array}{c} \text{CH}_2\text{-X} \\ \\ \text{CH-Y} \\ \\ \text{CH}_2\text{-Z} \end{array} \quad (\text{I})$				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HETEROARYL-SUBSTITUTED DEOXY GLYCERO-PHOSPHOETHANOLAMINES

TECHNICAL FIELD

5 The present invention relates to novel, therapeutically active deoxy glycerophosphoethanolamines substituted with a heteroaromatic cyclic moiety on the glyceryl backbone, pharmaceutical compositions comprising these compounds, intermediates
10 for making the compounds, and methods of making and using the compounds. The novel, therapeutically active compounds of the invention possess anti-tumor, anti-psoriatic, and anti-inflammatory activities.

15 BACKGROUND OF THE INVENTION

 Synthetic fatty alkyl and alkenyl ether glycerophospholipids with potential anti-tumor properties are reported in the literature. See, for example, F. Paltauf and A. Hermetter, Methods in
20 Enzymology 197, 134-149 (1991). The compound 1-O-octadecyl-2-O-methyl-sn-glycerophosphocholine (ET 18-OCH₃) has markedly potent anti-tumor activity. See R. Andreesen, "Ether Lipids in the Therapy of Cancer," Prog. Biochem. Pharmacol. 22, 118-131 (Karger,
25 Basel 1988). Treatment of cancer with a fatty alkyl ether glycerophosphoethanolamine component is also disclosed in U.S. Pat. No. 4,372,949. Halo substituted cytostatic analogs are described by H. Brachwitz et al., Chemistry and Physics of Lipids 31, 33-52 (1982).
30 Glycerophospholipids bearing a C₁₀₋₂₄ alkyl ether substituent in the 1-position, a cyclic amido group in the 2-position, and a cyclic ammonio group as part of the phosphoethanolamino function in the 3-position of the glyceryl backbone are described in U.S. Pat.
35 No. 4,650,791. Also disclosed in Pat. No. 4,650,791 are synthetic intermediates wherein the substituents are as described in the preceding sentence herein except that there is an hydroxyl group at the 3-position or hydroxyl groups at both the 1-position and the 3-position of the

- 2 -

glyceryl backbone. Glycero-phosphoethanolamines bearing a non-cyclic, substituted amino substituent in the 2-position and a lower C₁₋₅ alkyl ether substituent in the 1-position of the glyceryl backbone are disclosed in U.S. Pat. No. 5,116,992. Applicants are unaware, however, of the hereinafter described fatty alkyl and alkenyl ether glycero-phosphoethanolamines bearing a heteroaryl substituent.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphical representation of results from an *in vitro* MCF-7 cell inhibition assay of three compounds of the invention, designated CPR 1006, CPR 1007, and CPR 1008.

15 Figure 2 is a graphical representation of results from an *in vitro* MDA-MB-231 cell inhibition assay of three compounds of the invention, designated CPR 1006, CPR 1007, and CPR 1008.

Figure 3 is a graphical representation of results from an *in vitro* HL-60 cell inhibition assay of three compounds of the invention, designated CPR 1006, CPR 1007, and CPR 1008.

Figures 4, 5 and 6 present mean graphs from United States National Cancer Institute ("NCI") anti-cancer screening of compounds of the invention against multiple cell lines. Figure 4 presents data for the compound designated CPR 1006. Figure 5 presents data for the compound designated CPR 1007. Figure 6 presents data for the compound designated CPR 1008.

30 Figure 7 is a graphical representation of results from an *in vitro* PAM-212 cell inhibition assay of three compounds of the invention, designated CPR 1006, CPR 1007, and CPR 1008.

Figure 8 is a graphical representation of results from an *in vitro* RAW 264.7 cell macrophage inhibition chemiluminescence assay of three compounds of the invention, designated CPR 1006, CPR 1007 and CPR 1008.


- 3 -

DESCRIPTION OF THE INVENTION

The invention relates to novel, therapeutically active deoxy glycerophosphoethanolamines, pharmaceutical compositions comprising these therapeutically active compounds, and novel intermediates for use in making the therapeutically active compounds.

The therapeutically active compounds of the invention are represented by the general formula I:

10



15


I

wherein one of X, Y or Z is the fatty ether substituent -O-R, one is the heteroaryl ring substituent -Het, and one is the phosphoethanolamine substituent -O-PEA, provided that X, Y and Z are each a different substituent. The symbols R, Het and PEA are defined hereinafter. The invention encompasses all of the optically isomeric and stereoisomeric forms of the compounds of general formula I as well as salts of those compounds and all of the optically isomeric and stereoisomeric forms thereof.


25

More particularly, the therapeutically active, heteroaryl-substituted glycerophosphoethanolamines of the invention are represented by the general formulas Ia, Ib and Ic (collectively "the Formula I compounds"):


30



Ia



Ib



Ic

35

wherein the oxygens shown in Figures Ia, Ib and Ic are oxygens of the glyceryl backbone; R represents a substituted or unsubstituted straight or branched chain C_{10-24} alkyl or alkenyl, said substituent being one or more of halo, C_{1-3} alkoxy or cyano, provided that a double bond of said alkenyl does not involve the carbon atom of said

40

- 4 -

alkenyl that is bonded to the oxygen of the glyceryl backbone; Het represents a 5- to 9-membered heteroaryl mono- or bicyclic ring system with 1 to 4 nitrogens as the sole heteroatoms, one of which nitrogens is bonded to the carbon of the glyceryl backbone; and PEA, together with the oxygen of the glyceryl backbone to which PEA is bonded, represents a phosphoethanolamine of the formula:




wherein R^1 , R^2 and R^3 are each hydrogen or methyl, provided that at least one of R^1 , R^2 and R^3 is methyl; the enantiomeric and the cis- and trans-geometric isomers thereof; and the salts thereof.

When all three of R^1 , R^2 and R^3 are methyl, the $-\text{O}-\text{PEA}$ moiety is known as a phosphocholine moiety. When two of R^1 , R^2 and R^3 are methyl, the $-\text{O}-\text{PEA}$ moiety is known as a phospho-(N,N-dimethyl)ethanolamine moiety. When only one of R^1 , R^2 and R^3 is methyl, the $-\text{O}-\text{PEA}$ moiety is known as a phospho-(N-methyl)ethanolamine moiety. When none of R^1 , R^2 and R^3 is methyl, the $-\text{O}-\text{PEA}$ moiety is known as a phosphoethanolamine moiety.

Another aspect of the present invention are novel heteroaryl substituted glycerols, which are intermediates in processes for making the Formula I compounds. These novel intermediates of the invention are represented by a modification of general formula I in which the phosphoethanolamine substituent is replaced with an hydroxyl group.

More particularly, the intermediates of the invention are represented by the general formulas IIa, IIb and IIc (collectively "the Formula II compounds"):



- 5 -

wherein the oxygens shown in Figures IIa, IIb and IIc are oxygens of the glyceryl backbone; wherein R and Het are as defined above for the Formula I compounds; the enantiomeric and the cis- and trans-geometric isomers thereof; and the salts thereof.

As used herein, R is selected from the group consisting of (1) substituted or unsubstituted, preferably unsubstituted, C₁₀₋₂₄ alkyl groups, preferably C₁₄₋₂₀ alkyl and especially preferred C₁₆₋₁₈ alkyl, such as, for example, tetra-, penta-, hexa- hepta-, octa-, nonadecyl-, eicosyl-, or the branched analogs thereof; and (2) substituted or unsubstituted, preferably unsubstituted, C₁₀₋₂₄ alkenyl groups, preferably C₁₄₋₂₀ alkenyl and especially preferred C₁₆₋₁₈ alkenyl, whereby a double bond of the alkenyl group does not involve the carbon atom of said alkenyl that is bonded to the oxygen of the glyceryl backbone. Both the aforementioned alkyl and alkenyl groups can be substituted at one or more carbons, preferably at one, with substituents which do not interfere with syntheses of the compounds during the synthetic steps of making them. Preferred substituents are halo, C_{1,3} alkoxy or cyano. The term "halo" refers to any of the four halogens, chloro, bromo, iodo and fluoro, with chloro and fluoro being preferred.

Typical of the heteroaryl ring moieties included within the term "Het" are such 5- to 9 membered rings, including single and fused ring entities such as, for example, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl (also denoted as 1-triazolyl), tetrazol-1-yl, indolyl, benzimidazolyl, benztriazolyl, purinyl and the like, with imidazolyl and 1,2,4-triazolyl being preferred. Said rings may also be substituted with one or more substituents, preferably one, such as C_{1,3} alkyl, C_{1,3} alkoxy or a polar substituent such as cyano, nitro or methylsulfonyl. Typical of such substituted heteroaryl ring moieties are, for example, 1-(2-methylimidazolyl), 1-(4-methoxyindolyl),

-5/1-

1-(4-cyano-benztriazolyl) and the like. As used hereinafter, the term "Het-Compound" represents the

- 6 -

heteroaryl ring moiety with its additional hydrogen, i.e., Het-H, for example, pyrrole, pyrazole, imidazole, triazole and the like.

5 The preferred Formula I compounds, and the most preferred, which are of Formula Ia, are those wherein R is C₁₆₋₁₈ alkyl, Het is imidazolyl or 1,2,4-triazolyl, and -O-PEA is phosphocholine, for example:

1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine (which is designated "CPR 1006");
10 1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycero-3-phosphocholine (which is designated "CPR 1007"); and
1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine (which is designated "CPR 1008").

Other particular compounds of Formula Ia are:

15 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phospho-(N-methyl)ethanolamine;
1-O-hexadecyl-2-[1-(4-methoxyindolyl)]-2-deoxy-glycero-3-phosphocholine;
1-O-tetraeicosyl-2-(1-tetrazolyl)-2-deoxy-glycero-3-phospho-(N,N-dimethyl)ethanolamine;
20 1-O-hexadecyl-2-[1-(4-cyanobenzotriazolyl)]-2-deoxy-glycero-3-phosphocholine;
1-O-(trans-9-octadecenyl)-2-(1-imidazolyl)-2-deoxy-glycero-3-phospho-(N-methyl)ethanolamine; and
25 S-1-O-tetradecyl-2-purinyl-2-deoxy-glycero-3-phosphocholine.

Particular compounds of Formula Ib are:

R-1-O-hexadecyl-3-(1-imidazolyl)-3-deoxy-glycero-2-phosphocholine;
30 1-O-octadecyl-3-indolyl-3-deoxy-glycero-2-phospho-(N,N-dimethyl)ethanolamine;
1-O-(cis-9-hexadecenyl)-3-(1-tetrazolyl)-3-deoxy-glycero-2-phosphocholine; and
1-O-hexadecyl-3-(2-methylimidazolyl)-3-deoxy-glycero-2-phosphocholine.
35

- 7 -

Particular compounds of Formula Ic are:

1-(1-imidazolyl)-1-deoxy-2-O-hexadecyl-glycero-3-phosphocholine;

1-(1-triazolyl)-1-deoxy-2-O-(2-chloro-octadecyl)-glycero-3-phospho-(N-methyl)ethanolamine;

1-pyrrolyl-1-deoxy-2-O-(2-methoxy-octadecyl)-glycero-3-phosphocholine; and

1-(1-tetrazolyl)-1-deoxy-2-O-(9-octadecenyl)-glycero-3-phosphocholine.

The invention also comprehends salts of the compounds of the invention, including both the Formula I compounds and the Formula II compounds described hereinabove. These salts include acid addition salts, such as, for example, those made with hydrochloric, hydrobromic, nitric, sulfuric, phosphoric, carbonic, acetic, citric or lactic acids. The salts may also include those made with bases, such as, for example, sodium hydroxide, potassium hydroxide or calcium hydroxide. The salts of the invention are made by conventional methods well known to the skilled. The salts for therapeutic use of the Formula I compounds are pharmaceutically acceptable salts, as understood in the art.

CHEMISTRY

The compounds of the present invention may be prepared by the stepwise procedures outlined in the following Reaction Schemes and subsequent examples. As used in the Reaction Schemes, the symbols R, R¹, R², R³, PEA, and Het are as previously defined, the symbol Tr represents trityl, i.e., triphenylmethyl, and the symbol Ph represents phenyl. The thus-obtained compounds in the Reaction Schemes may be purified by conventional methods of the art, e.g. chromatography, recrystallization, etc.

The Formula I compounds and Formula II compounds have an asymmetric carbon atom (C2 position in the

- 8 -

glyceryl backbone) in their structures. Consequently these compounds may exist in the form of different R and S optically isomeric forms (enantiomers) or racemates. Substantially pure forms of either of the R- and S-isomer may be obtained, substantially free of the other, by the application of art-known resolution methodologies such as, for example, column chromatography using chiral columns, starting preparation from the R- or S-isomer of an appropriate precursor, for example, the starting Compound (A) shown in Reaction Scheme I hereinbelow.

In addition, cis- and trans-geometric isomers may also be present in the subject compounds, e.g. when R in Formulas I or II is C₁₀₋₂₄ alkenyl, due to the cis- and trans-configuration inherent with the double bond. Thus, by initially starting with an appropriate cis- or trans-precursor, the corresponding end product of the Formulas I compound or Formula II compound will be obtained.


All isomeric forms of the Formula I compounds and Formula II compounds, including pure enantomeric and geometric isomers and mixtures thereof, are intended to be within the scope of this invention. Unless otherwise specified, the compounds of the hereinafter examples are in racemic form.

Working up the individual stepwise products indicated in the following Reaction Schemes is advantageously carried out by standard methodologies, for example, by evaporating solvent from the reaction solution or precipitating the product from the reaction solution by dilution of the solution with an appropriate antisolvent (a solvent in which the product is less soluble than in the solvent of the reaction solution). The crude intermediate products obtained may be quite suitable, without further purification operations, for the preparation of the final products, which then may be purified. Particularly suitable methods for purifying

- 9 -

the Formula I and Formula II compounds are the conventional chromatographic methods, such as preparative thin-layer chromatography (TLC), column chromatography, adsorption chromatography, medium pressure liquid chromatography (MPLC) or high pressure liquid chromatography (HPLC).

REACTION SCHEME 1



Step 1:

35 The compounds of Formula (A) are known in the literature or are obtainable by art-recognized procedures. See, for example, A. Hermetter and F. Paltauf, Procedures for the Synthesis of Ether Lipids, p. 393 et.seq., in H.K. Mangold and F. Paltauf, "Ether Lipids", Academic Press, 1983, and F. Paltauf and A. Hermetter, Methods Enzymol. 197, 134-149 (1991). A solution of compound (A) in an amphoteric aprotic solvent, e.g. pyridine, tetrahydrofuran, dioxane or the like, is added dropwise with stirring to a solution of a

45 stoichiometric amount of p-toluenesulfonyl chloride,

- 10 -

preferably in solution with the same solvent. The reaction mixture may be maintained at room temperature until the reaction is essentially completed, and then subjected to conventional workup, for example, with appropriate organic extraction solvents, aqueous washes, drying, solvent evaporation, recrystallization and the like procedures, to yield the desired 2-p-toluenesulfonyl derivative (B).

10 Step 2:

Compound (B) is reacted with a stoichiometric amount of the desired Het-Compound in anhydrous dimethyl sulfoxide in the presence of sodium dimethylsulfinylmethide. Elevated temperatures are advantageously employed to enhance the rate of reaction, e.g. about 100° C. After the reaction is completed, conventional workup yields the desired 2-Het derivative (C).

20 Step 3:

Removal of the trityl function in Compound (C) to yield Compound (D) is readily accomplished by art-recognized procedures, e.g. by reaction with boron trifluoride in an appropriate organic solvent, e.g., methanol, at low to ambient temperature (see A. Hermetter and F. Paltauf, Chem. Phys. Lipids 29, 191 (1981)), followed by conventional workup.


Step 4:

30 The phosphoethanolamine moiety (PEA) is introduced by reaction of the hydroxyl in Compound (D) with 2-chloro-2-oxo-1,3,2-dioxaphospholane in an inert organic aprotic solvent, such as, for example, toluene (preferred), benzene, chloroform, diethyl ether, dioxane and the like, followed by reaction with an appropriate

- 11 -

amine, $\begin{array}{c} \text{R}^1 \\ | \\ \text{N}-\text{R}^2 \\ | \\ \text{R}^3 \end{array}$, to yield the desired compound (E).


REACTION SCHEME 2



Step 1:

35 The compounds of Formula (F) are known or are obtainable by art recognized procedures, for example, see P.N. Guivisdalsky and R. Bittmann, J. Org. Chem. 54, 4637-4642 (1989). In general, as illustrated below, the epoxide of glycidyl tosylate is opened in the presence

40 of boron trifluoride catalyst for reaction with the aliphatic alcohol, ROH, in an aprotic solvent, e.g., chloroform, to yield (F):



50

- 12 -

The R-, S- and racemic forms of glycidyl tosylate are commercially available and, accordingly, can be used as starting materials for making the enantiomers or racemates of compounds of Formula (F).

5 Step 1 is carried out to avoid side reactions in Step 2. Thus, the hydroxyl function of the compound of Formula (F) is protected under mild conditions by, for example, conventional acylation with a stoichiometric excess of benzoic acid chloride ($\text{Ph}-(\text{C}=\text{O})\text{Cl}$) in an
10 appropriate aprotic solvent, for example, toluene, chloroform, methylene chloride or the like and an excess of a sterically hindered base, for example, diisopropyl-ethylamine, at a temperature ranging from room temperature to the boiling point of the chosen
15 solvent. After completion of the reaction, conventional workup yields the desired compound of Formula (G).

Step 2:

Compound (G) is reacted with a stoichiometric
20 amount of the desired Het-Compound in anhydrous dimethyl sulfoxide in the presence of sodium dimethyl-sulfinylmethide. Elevated temperatures, e.g., about 100°C , are advantageously employed to enhance the rate of reaction. After the reaction is completed,
25 conventional workup yields the desired 1-Het derivative of Formula (H).

Step 3:

Removal of the protecting benzoyl group is
30 readily accomplished by saponification with an excess of a strong inorganic base such as sodium or potassium hydroxide in aqueous solution. The aqueous base is added to a solution of the compound of Formula (H) in an appropriate amphoteric, protic or aprotic solvent such
35 as, for example, methanol, ethanol, isopropanol, pyridine, dioxane or the like. After completion of the


- 13 -

reaction, conventional workup yields the desired compound of Formula (J).

Step 4:

5 The phosphoethanolamine moiety is introduced by
 reaction of the hydroxyl in Compound (J) with
 2-chloro-2-oxo-1,3,2-dioxaphospholane in an inert
 organic aprotic solvent, such as, for example, toluene
 (preferred), benzene, chloroform, diethyl ether, dioxane
 10 and the like, followed by reaction with an appropriate
 amine, $\begin{array}{c} \text{R}^1 \\ | \\ \text{N}-\text{R}^2 \\ | \\ \text{R}^3 \end{array}$, to yield the desired compound of
 15
 Formula (K).

REACTION SCHEME 3



- 14 -

Step 1:

The compounds of Formula (L) are readily obtained from the known precursor, 1,3-benzylidene-glycerol, with introduction of the R moiety analogous to the synthesis of 1-O-hexadecyl-2,3-isopropylidene-glycerol described by A. Hermetter and F. Paltauf, Procedures for the Synthesis of Ether Lipids, p. 391 et seq., in H.K. Mangold and F. Paltauf, Ether Lipids, Academic Press, 1983. Oxidative ring opening of the Formula (L) compound is carried out by treatment with a slight excess of N-bromosuccinimide (NBS) in carbon tetrachloride in the presence of excess barium carbonate. After the reaction is complete, conventional workup yields the compound of Formula (M).

Step 2:

Compound (M) is reacted with the desired Het-Compound as described in Step 2 of Reaction Scheme 1 to yield the Het-derivative of Formula (N).

Step 3:

Debenzoylation of the protected hydroxyl function of Compound (N) is carried out as described for Compound (H) in Reaction Scheme 2 to yield the Formula (O) compound.

Step 4:


Compound (O) is converted to Compound (P) under the same reaction conditions and molar ratios as described in Step 4 of Reaction Scheme 1.

- 15 -

REACTION SCHEME 4

This reaction scheme provides an alternative
chemical synthetic route for making the formula (P)

5 Compounds:



- 16 -

Step 1:

The compounds of Formula (Q) are either known or readily obtainable from 2-OR-1,3-benzylideneglycerol [see Compounds of Formula (L) in Reaction Scheme 3] by
5 conventional acid-catalyzed hydrolysis, for example, hydrochloric acid in methanol, of the benzylidene protective group, following procedures described in the literature; see, for example, E.O. Oswald et al., Lipids 1, p. 121 (1966); and A. Hermetter and F. Paltauf,
10 Procedures for the Synthesis of Ether Lipids, pp. 391-392, in H.K. Mangold and F. Paltauf, Ether Lipids, Academic Press, 1983).

Step 2:

15 Compound (Q) is tritylated in the conventional manner, for example, by reaction with triphenylchloromethane in an aprotic solvent, for example, pyridine, under anhydrous conditions at room temperature. After completion of the reaction,
20 conventional workup yields the desired trityl derivative (R).

Step 3:

25 A solution of Compound (R) in an amphoteric aprotic solvent, e.g., pyridine, tetrahydrofuran, dioxane or the like, is added dropwise with stirring to a solution of p-toluenesulfonyl chloride, preferably in solution with the same solvent. The reaction mixture may be maintained at room temperature until the reaction
30 is essentially completed, and then subjected to conventional workup to yield the desired tosyl derivative (S).

Step 4:

35 Replacement of the -O-Tosyl function in Compound (S) with a Het function is readily accomplished by the reaction of Compound (S) with the desired Het-Compound

- 17 -

in anhydrous dimethyl sulfoxide in the presence of sodium dimethylsulfinyl methide, followed by conventional workup to yield the desired 1-Het derivative of Formula (T).

5

Step 5:

Removal of the trityl function in Compound (T) to yield Compound (U) is readily accomplished by art-recognized procedures, similar to Step 3 in Reaction Scheme 1.

10

Steps 6 and 7:

The phosphoethanolamine moiety (PEA) is introduced by reaction of the hydroxyl in Compound (U) with 2-chloro-2-oxo-1,3,2-dioxaphospholane in an inert organic aprotic solvent to yield Compound (V), followed by reaction with an appropriate amine, $\text{NR}^1\text{R}^2\text{R}^3$, to yield the desired Compound (P), similar to Step 4 in Reaction Scheme 1.

20

UTILITY

The Formula I compounds, including the isomeric forms thereof and the pharmaceutically acceptable salts of those compounds (including all of the isomeric forms), are useful chemopreventive and adjuvant agents for the treatment of cancerous tumors and are useful therapeutic agents for treating inflammation and hyperproliferative skin diseases such as psoriasis.

25

A. ANTI-TUMOR

The anti-tumor activity of both naturally occurring and synthetic glycerol-derived ether lipids has been confirmed in the literature. See, for example, R. Andreesen, "Ether Lipids in the Therapy of Cancer", Prog. Biochem. Pharmacol., vol.22, pp. 118-131 (Karger, Basel 1988).

30

35

- 18 -

The following testing procedures using human tumor cell lines in *in vitro* assays, including the antitumor/anti-cancer screens conducted by the (NCI), demonstrate the marked anti-tumor (or antineoplastic) activity of the therapeutically useful compounds of the invention.

Assay

1. Human tumor cell lines, obtainable from the American Type Culture Collection (ATCC):
 - 10 a. MCF-7 (ATCC HTB 22): an estrogen receptor positive human breast carcinoma cell line (attachment dependent);
 - b. MDA-MB-231 (ATCC HTB 26): an estrogen receptor negative human breast carcinoma cell line
 - 15 (attachment independent); and
 - c. HL 60 (ATCC CCL 240): a promyelocytic leukemia cell line.
2. Culture media:
 - 20 a. For cell lines 1-a and 1-b: Dulbecco's Modified Eagle's Medium (DMEM) plus 10% Fetal Bovine Serum (FBS); and
 - b. For cell line 1-c: Roswell Park Memorial Institute-1640 (RPMI-1640) plus 20% FBS.
- 25 3. Standard protocol for culturing cell lines: in T-75 or T-150 flasks; 37°C; 95% air, 5% CO₂; 100% humidity.
 - a. Cell lines 1-a and 1-b are passaged when
 - 30 approximately 80% confluent; with trypsin (1 mg/mL) and EDTA (1 mM EDTA in Ca-Mg free Hank's balanced salt solution); at a 1:4 to 1:5 split.
 - b. Cell line 1-c is passaged by removing
 - 35 approximately 75% of the media and cell mixture and adding an equal amount of fresh media once or twice a week.

- 19 -

5 c. All procedures are performed aseptically in a Class II biological safety cabinet using standard BL-2 containment procedures. In order to prevent genetic drift in stock cell lines, fresh cultures are prepared at approximately monthly intervals with cells thawed from liquid nitrogen storage .

4. Methodology:

- 10 a. After cell passage, count cells with a hemocytometer;
b. Adjust concentration to approximately 10,000 cells per 100 μ L;
c. Pipette 100 μ L cell suspension into each well of a standard 96-well microtiter plate;
15 d. Preincubate 24 hours to allow cells to attach;
e. Add test compound dissolved in PEG-200 to achieve final concentration levels ranging from 0 to 30 μ M; and
f. Incubate 48 hours under standard culture
20 conditions and determine end points.

5. End Point (for cell lines 1-a and 1-b):

- a. Remove media and add approximately 100 μ L/well of cold methanol (0-5°C);
25 b. After 1 minute, remove methanol;
c. Add approximately 100 μ L crystal violet (CV) stain. (To prepare CV stain: dissolve 14 g dry crystal violet in 100 mL absolute ethanol; immediately before use, dilute 1 mL with 30 mL
30 distilled water);
d. After 15 minutes, remove stain and rinse cells with distilled water to remove residual stain;
e. Air-dry plates;
f. Read results from the wells using a standard
35 96-well microtiter plate reader (measuring absorbance at 600 nm);

- 20 -

g. Results: single point reading: the higher the absorbance, the higher the cell number; control - no test compound present in culture medium; calculate: Cell Number (as % of Control) =

5

$\frac{A(\text{compound})}{A(\text{control})} \times 100$, where A(compound)

is absorbance with test compound present in the culture medium and A(control) is absorbance of control;

10

h. Calculate: IC_{50} = Inhibitory Concentration 50%.

i. Results are represented in Figures 1 and 2, which illustrate the marked inhibition of cell growth at concentrations above $1\mu\text{M}$ of the compounds tested.

15

6. End Point (for cell line 1-C):

a. Follow assay directions provided with kit commercially available from Promega Corporation, Madison, Wisconsin, USA under the name "CellTiter 96™ AQ_{aqueous} Non-Radioactive Cell Proliferation Assay" (The assay is a non-radioactive, colorimetric method for determining number of viable cells based on cellular conversion of the tetrazolium salt, MTS, into a formazan that is soluble in tissue culture medium and is measured at 490 nm directly from 96-well assay plates without additional processing. See A. H. Cory et al., Cancer Commun. 3, 207 (1991); T. L. Riss and R. A. Moravec, Mol. Biol. Cell. 3 (Suppl.), 184a (1992); T. M. Buttke et al., J. Immunol. Methods 157, 233 (1993));

20

25

30

b. Read absorbance in the wells at 490 nm using a standard 96-well microtiter plate reader; the absorbance correlates with the cell number; determine Cell Number (as % of Control) following step 5(g) above.

35

- 21 -

c. The results are represented in Figure 3, which illustrates the marked inhibition of cell growth at concentrations above 0.3 μ M of the compounds tested.

5

Further evidence of the anti-tumor activity of the Formula I compounds are the results obtained in the NCI anti-cancer screening of such compounds against more than 50 different cell lines. In the mean graphs of
10 Figures 6-8, the relative sensitivity of each cell line to the test compound compared with the average sensitivity to the compound of all of the lines listed (and tested) is depicted in graphic form. The mean graph is constructed by projecting bars to the right or
15 left of the mean sensitivity of all of the cell lines, depending on whether the sensitivity of a cell line is either greater or less, respectively, than the average sensitivity of all of the lines. Furthermore, the length of each bar is proportional to the relative
20 sensitivity (relative to the mean sensitivity of all cell lines) of the cell line corresponding to the bar. A more detailed description of the NCI screen for anti-tumor/ant-cancer activity and mean graphs to depict results from screening a composition are reported by
25 M.R. Grever et al., "The National Cancer Institute: Cancer Drug Discovery and Development Program", Seminars in Oncology, Vol.19, No. 6 (December), 1992: pp.622-638.

Figure 4 depicts a mean graph from NCI anti-tumor/anti-cancer screening for the compound
30 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine (CPR 1006).

Figure 5 depicts a mean graph from NCI anti-tumor/anti-cancer screening for the compound
1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycero-3-
35 phosphocholine (CPR 1007).

Figure 6 depicts a mean graph from NCI anti-tumor/anti-cancer screening for the compound

- 22 -

1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine (CPR 1008).

In each mean graph, a mean of the logarithms of the concentrations of the compound, to which the mean graph corresponds, that produces a particular level of response (e.g., GI50, TGI, or LC50) for all the cell lines in the screen forms the anchor point. The individual response of each cell line to the compound is then depicted by a bar graph either to the right or left of the mean, as previously explained. The notations GI50, TGI, and LC50 refer to the concentrations of the compound in the assay that produces 50% growth inhibition, total growth inhibition, or 50% cell death, respectively.

From the data in Figures 1 - 6, it is evident that the Formula I compounds demonstrate marked anti-tumor activity against a broad range of human tumor cell lines, particularly against breast, colon and leukemia lines. In view of such activity, the Formula I compounds (and pharmaceutically acceptable salts thereof) are active against a wide spectrum of mammalian (including human) tumors and cancerous growths such as cancers of the oral cavity and pharynx (lip, tongue, mouth, pharynx), esophagus, stomach, small intestine, large intestine, rectum, liver and biliary passages, pancreas, larynx, lung, bone, connective tissue, skin, colon, breast, cervix, uterus, corpus endometrium, ovary, prostate, testes, bladder, kidney and other urinary tissues, eye, brain and central nervous system, thyroid and other endocrine glands, leukemias (lymphocytic, granulocytic, monocytic), Hodgkin's disease, non-Hodgkin's lymphomas, multiple myeloma, etc. Herein the terms "tumor", "cancer" and "cancerous growths" are used synonymously.

This invention thus provides a method of treating a tumor in a mammal afflicted with same comprising administering to said mammal an anti-tumor-effective

- 23 -

amount of a Formula I compound or a pharmaceutically acceptable salt thereof.

Also, then, the invention provides pharmaceutical compositions comprising an anti-tumor-effective amount
5 of a Formula I compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

B. ANTI-PSORIASIS

10 Psoriasis is a chronic inflammatory dermatosis characterized, in part, by hyperproliferation of keratinocytes and release of pro-inflammatory cytokines. Compounds that reduce hyperproliferation of
15 keratinocytes *in vitro* are therefore likely to have utility in the control of psoriasis. The PAM-212 cell line is a keratinocyte line that was isolated and cultivated from newborn BALB/c mice (see S.H. Yuspa et al., Cancer Research, 40, 4694-4703, December, 1980) and is now readily available to the skilled in the art. The
20 cells of the PAM-212 line appear to retain many characteristics of normal keratinocytes. As shown hereinafter, Formula I compounds markedly inhibit proliferation of these cells *in vitro*, thus indicating their usefulness (and that of their pharmaceutically
25 acceptable salts) in treating psoriasis.

ASSAY

1. Cell line: PAM-212 murine keratinocyte cell line described in S.H. Yuspa, *supra*.
- 30 2. Culture medium: 1:1 DMEM and Ham's F-12 with 10% FBS.
3. Culture conditions are the same as those described hereinabove in parts 3(a) and 3(c) of the assay protocol for anti-tumor activity.
4. Methodology is the same as that described hereinabove
35 in part 4 of the assay protocol for anti-tumor activity, except that, with reference to part 4(f) of the assay protocol for anti-tumor activity, incubation in this

- 24 -

case is conducted for 72 hours (rather than 48 hours) under standard culture conditions prior to end point determination.

5 5. End point determination and analysis is as described hereinabove in part 5 of the assay protocol for anti-tumor activity.

6. The results are represented in Figure 7, which illustrates the marked keratinocyte-proliferation inhibition, and consequently anti-psoriatic activity, at
10 concentrations above 10 μ M of Formula I compounds of the invention (and pharmaceutically acceptable salts thereof).

The instant invention thus provides a method of
15 treating psoriasis in a mammal afflicted with same comprising administering to said mammal an anti-psoriatic-effective amount of a Formula I compound or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutical compositions
20 comprising an anti-psoriatic-effective amount of a Formula I compound (or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier.

C. ANTI-INFLAMMATORY

25 Inflammation is a complex process, involving a variety of cell types including macrophages. See, for example, S.L. Kunkel, "Inflammatory Cytokines", pp. 1-15, in Manual of Vascular Mediators, P.A. Ward, Editor, produced by the publishers of Hospital Practice.
30 References relative to macrophages are numerous, including, for example, J. Immunology 119:950-954 (1977) and Cell 15: 261-267 (1978).

Macrophages are activated by infection and a wide variety of non-infectious irritants and proinflammatory
35 agents. Upon activation, macrophages participate in a variety of reactions. They may phagocytize bacteria and kill them by either oxygen-dependent or oxygen-

- 25 -

independent pathways. They are activated to increase oxygen consumption and production of reactive oxygen species (for example, superoxide). In addition, they release a variety of inflammatory cytokines, including
5 several interleukins and tumor necrosis factor α (TNF α). Inhibition of any of these pathways can lead to reduced inflammation.

The RAW 264.7 cell line (ATCC TIB 71) is a murine monocyte/macrophage line the cells of which show many of
10 the differentiative functions of a macrophage. The cells are capable of phagocytosis and undergo an oxidative burst in response to signals that occasion an oxidative burst in macrophages. Agents that inhibit the activation of cells of the RAW 264.7 line *in vitro* are
15 therefore inhibitors of critical steps in inflammatory processes.

CHEMILUMINESCENCE (CL) ASSAY - BACKGROUND

Activation of macrophages and other phagocytic
20 cell types initiates a cascade of actions that include increased oxygen consumption (respiratory burst) and production of oxygen radicals. These events can be measured in a variety of ways, including chemiluminescence based on the addition of luminol (see
25 M.A. Trush et al, 1978, The generation of chemiluminescence by phagocytic cells. Methods in Enzymology 57: 462-494). Because chemiluminescence is induced by the increased production of oxygen radicals, that are thought to be important in intracellular
30 killing of bacteria, chemiluminescence has long been used as an index of phagocytic cell activity. In addition, oxygen radical production is associated with inflammatory responses and may have adverse consequences in inflammation that is not due to infection (non-
35 infectious inflammation). For this reason, oxygen radical production associated with macrophage activation is of critical importance in studies of the inflammatory

- 26 -

process. Agents that reduce macrophage activation are likely to have utility as anti-inflammatory agents. Since luminescence generated from luminol is a recognized marker of macrophage activation (due to the associated production of oxygen radicals), the finding that Formula I compounds of the present invention (and pharmaceutically acceptable salts thereof) strongly inhibit chemiluminescence in macrophages correlates to the usefulness of these compounds (and salts) in ameliorating inflammation.

ASSAY

1. Cell line: RAW 264.7 (ATCC TIB 71);
2. Culture medium: DMEM with 10% FBS (attachment dependent);
3. Standard protocol for culturing cell lines: in T-75 or T-150 flasks; 37°C; 95% air, 5% CO₂; 100% humidity;
4. Cell lines are passaged when approximately 80% confluent; with trypsin (1 mg/mL) and EDTA (1 mM EDTA in Ca-Mg free Hank's balanced salt solution); at a 1:4 to 1:5 split;
5. Trypsinize the cells and count with a hemocytometer;
6. Adjust concentration of cells to approximately 1,000,000 cells per mL;
7. Suspend cells in DMEM lacking phenol red and without FBS;
8. Pipette 1 mL of cells into a standard luminometer cuvet (12 x 75), commercially obtainable from Analytical Luminescence Laboratories, San Diego, California, USA;
9. Add luminol to final concentration of 1μM;
10. Add test compound (0, 1, 3, 10, 30μM);
11. After 2 minutes, add 100 nanograms of phorbol myristate acetate (PMA);
12. Wait 1 minute and read photo counts (i.e., luminescence) on a Monolight 2010 luminometer available from Analytical Luminescence Laboratories, San Diego;

- 27 -

13. The results are represented in Figure 8, which illustrates the marked decrease in measured luminescence units by the compounds tested at concentrations above 3 μ M.

5 14. The results are also represented in Table 1, which tabulates the measured cell counts at the indicated concentration of tested compound.

Table 1

Concentration (μ M)	Luminescence Units		
	CPR 1006	CPR 1007	CPR 1008
0	2,590,848	2,414,436	2,182,532
1	2,957,236	1,063,719	1,749,777
3	1,738,755	322,449	333,006
15 10	12,988	30,452	77,061
30	4,660	5,095	11,654

The instant invention thus provides a method of treating inflammation in a mammal afflicted with same comprising administering to said mammal an anti-inflammatory-effective amount of a Formula I compound or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutical compositions comprising an anti-inflammatory-effective amount of a Formula I compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

FORMULATIONS

Formulations of the present invention, for medical use, comprise an active compound, i.e., a Formula I compound or a pharmaceutically acceptable salt thereof, together with an acceptable carrier therefor and optionally other therapeutically active ingredients. The carrier must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

- 28 -

The present invention, therefore, further provides a pharmaceutical formulation comprising a Formula I compound together with a pharmaceutically acceptable carrier thereof.

5 The formulations include those suitable for oral, rectal or parenteral (including subcutaneous, intramuscular and intravenous) administration. Preferred are those suitable for oral or parenteral administration. Topical formulations are also included,
10 for, for example, anti-psoriatic usage.

 It is noted that the Formula I compounds have relatively low melting points which, accordingly, may need to be taken into consideration in, for example, preparing tablets on a commercial scale where the heat
15 of compression may be a factor. The Formula I compounds are also rather insoluble in water and, accordingly, liquid formulations which account for this factor may be made according to art-recognized pharmaceutical techniques, for example, administration dispersed in
20 water as micelles, an injectable wherein the active compound is dissolved in a suitable solvent or co-solvent such as an appropriate polyethylene glycol, or a propylene glycol or the like, or a sealed gelatin capsule enclosing an oily solution of the active
25 compound, or a suppository of the active compound in a conventional suppository base such as cocoa butter, or a liposome formulation, for example, the active compound and a glycerophospholipid such as phosphatidylcholine. In any event, the aforementioned characteristics of the
30 Formula I compounds are not uncommon in the pharmaceutical area and, accordingly, art-recognized pharmaceutical techniques are employed to prepare appropriate formulations for such compounds as those of Formula I or pharmaceutically acceptable salts thereof.

35 The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods

- 29 -

include the step of bringing the active compound into association with a carrier which constitutes one of more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active
5 compound into association with a liquid carrier or a finely divided solid carrier and then, if necessary, shaping the product into desired unit dosage form.

Formulations of the present invention suitable for oral administration may be presented as discrete
10 units such as capsules, cachets, tablets, boluses or lozenges, each containing a predetermined amount of the active compound; as a powder or granules; or in liquid form, e.g., as a suspension, solution, syrup, elixir, emulsion, dispersion, or the like.

15 A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form, e.g., a powder or granules, optionally mixed with
20 accessory ingredients, e.g., binders, lubricants, inert diluents, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered active compound with any suitable carrier.

25 Formulations suitable for parenteral administration conveniently comprise a sterile preparation of the active compound in, for example, a polyethylene glycol 200 or propylene glycol solution which is preferably isotonic with the blood of the
30 recipient. Liposomes would also provide a convenient formulation.

Useful formulations also comprise concentrated solutions or solids containing the compound of Formula I which upon dilution with an appropriate solvent give a
35 solution suitable for parenteral administration.

Preparations for topical or local applications, which are, for example, conventional for anti-psoriatic

- 30 -

usage, comprise aerosol sprays, lotions, gels, ointments, etc. and pharmaceutically acceptable vehicles therefore such as, for example, lower aliphatic alcohols, polyglycerols such as glycerol, polyethyleneglycerol, esters of fatty acids, oils and fats, silicones, and other conventional topical carriers. Again, liposomes provide a convenient formulation.

In topical formulations, the compounds of Formula I are preferably utilized at concentrations of from about 0.1% to about 5.0% percent by weight.

In addition to the aforementioned ingredients, the formulations of this invention may further include one or more optional accessory ingredient(s) utilized in the art of pharmaceutical formulations, e.g., diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, suspending agents, preservatives (including antioxidants) and the like.

The amount of compound of Formula I required to be effective for the indicated activity will, of course, vary with the individual mammal being treated and is ultimately at the discretion of the medical or veterinary practitioner. The factors to be considered include the condition being treated, the route of administration, the nature of the formulation, the mammal's body weight, surface area, age and general condition, and the particular compound to be administered. However, a suitable effective dose is in the range of about 0.1 to about 200 mg/kg body weight per day, preferably in the range of about 1 to about 100 mg/kg per day. The total daily dose may be given as a single dose, multiple doses, e.g., two to six times per day, or by intravenous infusion for a selected duration. Dosages above or below the range cited above are within the scope of the present invention and may be administered to the individual patient if desired and necessary.

- 31 -

For example, for a 75 kg mammal, a dose range would be about 75 to about 7500 mg per day, and a typical dose would be about 800 mg per day. If discrete multiple doses are indicated, treatment might typically be 200 mg of a compound of Formula I given 4 times per day.

The following examples are intended to illustrate and not to limit the scope of the present invention. Examples 1-8 are illustrative of Reaction Scheme 1; examples 9-17 are illustrative of Reaction Scheme 2; examples 18-26 are illustrative of Reaction Scheme 3; and examples 27-31 are illustrative of Reaction Scheme 4.

15

EXAMPLE 1

A. 1-O-Octadecyl-2-O-p-Toluenesulfonyl-3-O-Trityl-Glycerol

A solution of 1-O-octadecyl-3-O-trityl-glycerol (173.51 g, 295.63 mmol) in 895 mL water-free pyridine is added dropwise to a solution of p-toluenesulfonyl chloride (88.49 g, 464.15 mmol) in 670 mL water-free pyridine with constant stirring. The reaction mixture is kept at ambient temperature (20-23°C) for two days. Diethyl ether (Et₂O) (2.8 L) is added and the organic phase is washed six times with water, twice with 0.5 N HCl (500 mL each), twice with diluted aqueous sodium carbonate, and then washed with water until neutral. After drying the organic phase over sodium sulfate, the solvent is removed under vacuum. The residue is triturated with isopropanol (1140 mL) with stirring until the product crystallizes. After cooling to 4°C, the product, 1-O-octadecyl-2-O-p-toluenesulfonyl-3-O-trityl-glycerol, is isolated by filtration, washed with isopropanol and dried under vacuum.

Yield: 190.14 g (86.91%); m.p. 56-58°C; R_f value (TLC on silica gel 60) of 0.38 with benzene as the developing solvent; and R_f of 0.74 with benzene/methanol (50/2).

- 32 -

B. By following the procedure of Example 1-A, except that an equivalent amount of 1-O-hexadecyl-3-O-trityl-glycerol is utilized as the starting Formula (A) Compound, there is obtained as final product the
5 corresponding 1-O-hexadecyl-2-O-p-toluenesulfonyl-3-O-trityl-glycerol; yield 73%; Rf value: 0.37 benzene; 0.79 benzene/methanol (50/2).

EXAMPLE 2

10 The procedure of Example 1-A is followed except that an equivalent amount of the appropriate 1-O-R-3-O-trityl-glycerol is utilized as the starting Formula (A) compound to yield the following respective Formula (B) compounds:

15 a. 1-O-eicosyl-2-O-p-toluenesulfonyl-3-O-trityl-glycerol;
b. S-1-O-octadecyl-2-O-p-toluenesulfonyl-3-O-trityl-glycerol;
c. 1-O-(1-methylheptadecyl)-2-O-p-toluenesulfonyl-3-O-trityl-glycerol;
20 d. 1-O-tetradecyl-2-O-p-toluenesulfonyl-3-O-trityl-glycerol;
e. R-1-O-hexadecyl-2-O-p-toluenesulfonyl-3-O-trityl-glycerol;
25 f. 1-O-(cis-9-octadecenyl)-2-O-p-toluenesulfonyl-3-O-trityl-glycerol; and
g. 1-O-(trans-8-hexadecenyl)-2-O-p-toluenesulfonyl-3-O-trityl-glycerol.

EXAMPLE 3

30 A. 1-O-Octadecyl-2-(1-Imidazolyl)-2-Deoxy-3-O-Trityl-Glycerol
1-O-octadecyl-2-p-toluenesulfonyl-3-O-trityl-glycerol (106.56 g, 144 mmol) and imidazole
35 (29.28 g, 430 mmol) are dissolved in water-free dimethyl sulfoxide (800 mL) at 100°C. A solution of sodium dimethylsulfinylmethide, prepared from metallic sodium

- 33 -

(6.72 g) in 800 mL dimethyl sulfoxide, is added and the resultant mixture is stirred at 100°C for 72 hours. After cooling, diethyl ether (2000 mL) is added. The organic phase is washed six times with water (1500 mL each) and dried over sodium sulfate. The solvent is removed under vacuum.

The thus-obtained crude product (87.6 g), consisting of starting material and the desired product, according to thin layer chromatography (TLC) analysis, is purified by medium pressure liquid chromatography (MPLC). A solution of the crude product (0.6 g) in methylene chloride (2.0 mL) is applied onto a MPLC-column (30 x 3 cm) filled with silica gel 35-70 with the following parameters: pressure—0.9 atmosphere; flow rate—500 mL/hour; solvent—methylene chloride (fractions 1-35) and methylene chloride/methanol (40/2 v/v); fraction volumes of 10-15 mL are collected; yield is about 60%; purified 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-2- deoxy-3- O-trityl-glycerol; m.p. 53-58°C; Rf value: 0.30 benzene/methanol 50/5.

MPLC purification of a larger amount of the crude product (1.85 g) in 3 mL methylene chloride/diethyl ether (40/2.5 v/v) is also carried out using a 40 x 4 cm column (pressure—0.9 atmosphere, flow rate—700 mL/hr).

B. The procedure of Example 3-A is followed, except that an equivalent amount of 1,2,4-triazole is substituted for the imidazole used therein, to yield as final product (oily liquid) the corresponding 1-O-octadecyl-2-(1-triazolyl)-2-deoxy-3-O-trityl-glycerol; Rf value: 0.31 methylene chloride/ether 3/1; yield 83% after purification by column chromatography.

C. By following the procedure of Example 3-A, except that an equivalent amount of 1-O-hexadecyl-2-O-p-

- 34 -

toluenesulfonyl-3-O-trityl-glycerol is utilized as the starting Formula (B) compound, there is obtained as final product the corresponding 1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-3-O-trityl-glycerol;

- 5 Rf value: 0.29 toluene/methanol 50/3; yield 45% after purification by column chromatography.

EXAMPLE 4

10 The procedure of Example 3-A is followed except that an equivalent amount each of the appropriate Formula (B) compound and the appropriate Het-Compound is utilized as the initial reactants to yield the following respective Formula (C) compounds as final products:

- 15 a. 1-O-eicosyl-2-(1-imidazolyl)-2-deoxy-3-O-trityl-glycerol;
b. S-1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-3-O-trityl-glycerol;
c. 1-O-(1-methylheptadecyl)-2-pyrrolyl-2-deoxy-3-O-trityl-glycerol;
20 d. 1-O-tetradecyl-2-benztriazolyl-2-deoxy-3-O-trityl-glycerol;
e. R-1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-3-O-trityl-glycerol;
f. 1-O-(cis-9-octadecenyl)-2-pyrazolyl-2-deoxy-3-O-trityl-glycerol; and
25 g. 1-O-(trans-8-hexadecenyl)-2-indolyl-2-deoxy-3-O-trityl-glycerol.

EXAMPLE 5

- 30 A. 1-O-Octadecyl-2-(1-Imidazolyl)-2-Deoxy-Glycerol

A solution of boron trifluoride (50%) in methanol (88 mL) is added to a solution of 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-3-O-trityl-glycerol (87.6 g, 137.52 mmol) in methylene chloride (2000 mL) and the resultant dark green solution is kept at ambient
35 temperature for 24 hours. After washing with water (500 mL) the color changes to yellow. The resulting emulsion

- 35 -

is separated into two phases by the addition of sodium chloride. The organic phase is washed consecutively with diluted aqueous sodium carbonate and water until neutral. After drying over sodium sulfate, the solvent
5 is removed under vacuum. The thus-obtained crude 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycerol is purified by column chromatography as follows:

column: Prep 500 silica (Waters Chromatography, Milford, Massachusetts, USA);
10 solvent: methylene chloride/methanol/conc. ammonia 40/3.5/0.1 v/v/v;
pressure: 13 bar;
flow rate: 200-250 mL/hr;
yield: 19.3 g (68%);
15 m.p.: 56-58°C;
Rf value: 0.21 CH₂Cl₂/CH₃OH/c.NH₃ 40/3.5/0.1 v/v/v; 0.38 benzene/methanol 45/5 v/v.

Note: The workup procedure might be improved with 4N sodium hydroxide (about 10% excess) added directly to
20 the reaction mixture with stirring, followed by washing the organic phase until neutral.

B. By following the procedure of Example 5-A, except that an equivalent amount each of the 2-(1-triazolyl)
25 and the 2-(1-imidazolyl) derivatives from Examples 3-B and 3-C, respectively, is utilized as the starting Formula (C) compound, the following respective final products are obtained:
1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycerol; m.p.
30 73-78°C; Rf value: 0.42 (methylene chloride/methanol 45/5); 0.13 (benzene/methanol 50/5); yield 83% after purification by column chromatography; and
1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycerol; m.p.
52-56°C; Rf value: 0.50 methylene chloride/methanol/
35 water 40/15/1.5; yield 79% after purification by column chromatography.

- 36 -

EXAMPLE 6

The procedure of Example 5-A is followed, except that an equivalent amount each of the Formula (C) compounds from Example 4 is substituted for the 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-3-O-trityl-glycerol of Example 5-A, to yield the following respective Formula (D) compounds:

- a. 1-O-eicosyl-2-(1-imidazolyl)-2-deoxy-glycerol;
- b. S-1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycerol;
- 10 c. 1-O-(1-methylheptadecyl)-2-pyrrolyl-2-deoxy-glycerol;
- d. 1-O-tetradecyl-2-benztriazolyl-2-deoxy-glycerol;
- e. R-1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycerol;
- f. 1-O-(cis-9-octadecenyl)-2-pyrazolyl-2-deoxy-glycerol; and
- 15 g. 1-O-(trans-9-hexadecenyl)-2-indolyl-2-deoxy-glycerol.

EXAMPLE 7

A. 1-O-Octadecyl-2-(1-Imidazolyl)-2-Deoxy-Glycero-3-Phosphocholine

20 3.95 Grams (10 mmol) of 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycerol is dissolved in water-free toluene (150 mL). After removal of 25 mL solvent under vacuum, triethylamine (1.16 g, 11.5 mmol) in dry toluene (20 mL) is added slowly with stirring, followed by dropwise addition of a solution of 2-chloro-2-oxo-1,3,2-dioxaphospholane (1.58 g, 11 mmol) in 20 mL toluene. (Note: 2-chloro-2-oxo-1,3,2-dioxaphospholane is not stable under storage and decomposes if heated.) The reaction mixture is stirred for 24 hours. Two additional portions of 0.58 g and 0.79 g triethylamine dissolved in toluene (15 mL each) are added after 24 and 48 hours, respectively. The resultant precipitate of triethylamine hydrochloride is removed by filtration and washed with toluene.

35 The filtered organic solvent is removed under vacuum and the residue is triturated in a pressure bottle with 130 mL dry acetonitrile. After addition of

- 37 -

12 g dry trimethylamine, the resultant reaction mixture is stirred at 60° C for 24 hours (use round bottom flask and fix glass stopper by a mechanical device). After cooling to 0° C, the resultant precipitate is separated
5 by filtration followed by consecutive washing with acetonitrile and acetone. Residual solvent is removed under vacuum. Yield of crude 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine: 5.54 g (98.86%), which is purified as follows:

10 Purification by column chromatography:

A solution of the crude product (5.4 g) in 7 mL methylene chloride/methanol (7/3, v/v) is applied onto a column Prep 500 silica (Waters Chromatography);
15 pressure: 23 bar;
flow rate: 200 mL/min;
solvent: methylene chloride/methanol/2 N ammonia (40/30/6, v/v/v);
yield: 57%;
20 Rf value: 0.19 CH₂Cl₂/CH₃OH/c.NH₃ (40/30/6, v/v/v).

Further purification:

The product is dissolved in ethanol (15 mL) and the resultant solution is passed over alumina (10 g, coarse, not for column chromatography).

25

B. By following the procedure of Example 7-A, except that an equivalent amount each of the 2-(1-triazolyl) and the 2-(1-imidazolyl) derivatives from Example 5-B is utilized as the starting Formula (D) compound, the following respective final products are obtained:
30 1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycero-3-phosphocholine; Rf value: 0.17 CH₂Cl₂/CH₃OH/c.NH₃ 40/30/6; yield 23% after purification by column chromatography; and
35 1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-

- 38 -

phosphocholine; Rf value: 0.18 CH₂Cl₂/CH₃OH/c.NH₃
40/30/6; yield 37% after purification by column
chromatography.

- 5 C. The compounds, 1-O-octadecyl-2-(1-imidazolyl)-2-
deoxy-glycero-3-phospho-(N-methyl)-ethanolamine and the
corresponding -3-phospho-(N,N-dimethyl)-ethanolamine,
are each prepared in a manner analogous to that
described for the -3-phosphocholine of Example 7-A,
10 except that an equivalent amount each of methylamine and
dimethylamine, respectively, is substituted for the
trimethylamine used therein.

EXAMPLE 8

- 15 The procedure of Example 7-A is followed, except
that an equivalent amount each of the Formula (D)
compounds from Example 6 is substituted for the
1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycerol of
Example 7-A, to yield the following respective Formula
20 (E) compounds:

- a. 1-O-eicosyl-2-(1-imidazolyl)-2-deoxy-glycero-3-
phosphocholine;
- b. S-1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-
phosphocholine;
- 25 c. 1-O-(1-methylheptadecyl)-2-pyrrolyl-2-deoxy-
glycero-3-phosphocholine;
- d. 1-O-tetradecyl-2-benztriazolyl-2-deoxy-glycero-3-
phosphocholine;
- e. R-1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-
30 phosphocholine;
- f. 1-O-(cis-9-octadecenyl)-2-pyrazolyl-2-deoxy-
glycero-3-phosphocholine; and
- g. 1-O-(trans-9-hexadecenyl)-2-indolyl-2-deoxy-
glycero-3-phosphocholine.

35

EXAMPLE 9

1-O-Octadecyl-2-Benzoyl-3-O-p-Toluenesulfonyl-Glycerol

- 39 -

9.98 Grams (20 mmol) of Compound (F), with R being $C_{18}H_{37}$, is dissolved in 150 mL dry toluene. 3.88 grams (30 mmol) of diisopropyl-ethylamine is added followed by a solution of 4.19 g (30 mmol) of benzoic acid chloride in 50 mL toluene within 10 minutes. The clear reaction mixture is allowed to stand 48 hours at room temperature, washed with water, washed twice with saturated sodium bicarbonate solution, again with water, dried over sodium sulfate, filtered and evaporated to dryness. The residual waxy solid (12.2 g) of 1-O-octadecyl-2-benzoyl-3-O-p-toluenesulfonyl-glycerol is used without further purification in the succeeding step.

15

EXAMPLE 10

The procedure of Example 9 is followed, except that an equivalent amount of the appropriate Formula (F) compound is utilized as the initial reactant, to yield the following respective Formula (G) compounds:

- 20 a. 1-O-tetradecyl-2-benzoyl-3-O-p-toluenesulfonyl-glycerol;
b. 1-O-hexadecyl-2-benzoyl-3-O-p-toluenesulfonyl-glycerol;
c. 1-O-eicosyl-2-benzoyl-3-O-p-toluenesulfonyl-glycerol;
25 d. S-1-O-octadecyl-2-benzoyl-3-O-p-toluenesulfonyl-glycerol: and
e. R-1-O-hexadecyl-2-benzoyl-3-O-p-toluenesulfonyl-glycerol.

30

EXAMPLE 11

A. 1-O-Octadecyl-2-Benzoyl-3-(1-Triazolyl)-3-Deoxy-Glycerol

35 12.2 grams (approximately 20 mmol) of the waxy solid obtained in Example 9 is reacted with the Het-Compound, triazole, under the same reaction conditions and molar ratios as described for Step 2 of

- 40 -

Reaction Scheme 1. After purification by column chromatography (400 g silica gel; toluene as the mobile phase), about 5.37 g (53.73% theoretical yield) of 1-O-octadecyl-2-benzoyl-3-(1-triazolyl)-3-deoxy-
5 glycerol is obtained: R_f value of 0.65; silica gel; methylene chloride/methanol 45/5.

EXAMPLE 12

By following the procedure of Example 11, except
10 that an equivalent amount each of the appropriate Formula (G) compound of Example 10 and the appropriate Het-Compound is utilized as the initial reactants, the following respective final products of Formula (H) are obtained:

- 15 a. 1-O-tetradecyl-2-benzoyl-3-(1-imidazolyl)-3-deoxy-glycerol;
- b. 1-O-hexadecyl-2-benzoyl-3-(1-triazolyl)-3-deoxy-glycerol;
- c. 1-O-eicosyl-2-benzoyl-3-pyrrolyl-3-deoxy-glycerol;
- 20 d. S-1-O-octadecyl-2-benzoyl-3-benzotriazolyl-3-deoxy-glycerol;
- e. R-1-O-hexadecyl-2-benzoyl-3-indolyl-3-deoxy-glycerol;
- f. 1-O-(9-octadecenyl)-2-benzoyl-3-pyrazolyl-3-deoxy-
25 glycerol; and
- g. 1-O-(9-hexadecenyl)-2-benzoyl-3-(1-triazolyl)-3-deoxy-glycerol.

EXAMPLE 13

30 1-O-Octadecyl-2-Hydroxy-3-(1-Triazolyl)-3-Deoxy-Glycerol
5.0 Grams (10 mmol) of 1-O-octadecyl-2-benzoyl-3-(1-triazolyl)-3-deoxy-glycerol is dissolved in 100 mL ethanol and 5 mL of 4N sodium hydroxide (20 mmol) in water is added at one time and allowed to stand
35 overnight at room temperature. The ethanol is then removed under reduced pressure. 50 mL of 0.2N acetic acid in water and 150 mL toluene are then added. The

- 41 -

phases are separated and the toluene phase is washed two times with 50 mL water, dried over sodium sulfate and brought to dryness. The semisolid residue (3.82 g, 96.56% theoretical) of 1-O-octadecyl-2-hydroxy-3-(1-triazolyl)-3-deoxy-glycerol shows one spot in TLC; $R_f = 0.39$, silica gel, methylene chloride/methanol 45/5, and is utilized in the succeeding step without further purification.

10

EXAMPLE 14

Saponification of each of the Formula (H) compounds of Example 12 in accordance with the teaching of Example 13 yields the following respective compounds of Formula (J):

- 15 a. 1-O-tetradecyl-2-hydroxy-3-(1-imidazolyl)-3-deoxy-glycerol;
b. 1-O-hexadecyl-2-hydroxy-3-(1-triazolyl)-3-deoxy-glycerol;
c. 1-O-eicosyl-2-hydroxy-3-pyrrolyl-3-deoxy-glycerol;
20 d. S-1-O-octadecyl-2-hydroxy-3-benztriazolyl-3-deoxy-glycerol;
e. R-1-O-hexadecyl-2-hydroxy-3-indolyl-3-deoxy-glycerol;
f. 1-O-(9-octadecenyl)-2-hydroxy-3-pyrazolyl-3-deoxy-glycerol; and
25 g. 1-O-(9-hexadecenyl)-2-hydroxy-3-(1-triazolyl)-3-deoxy-glycerol.

EXAMPLE 15

30 1-O-Octadecyl-3-(1-Triazolyl)-3-Deoxy-Glycero-
2-Phosphocholine

The procedure of Step 4 of Reaction Scheme 1 is followed, reacting 1.88g (5 mmol) of the Formula (J) compound, 1-O-octadecyl-2-hydroxy-3-(1-triazolyl)-2-deoxy-glycerol, under the same reaction conditions and
35 molar ratios, with 2-chloro-2-oxo-1,3,2-dioxaphospholane and subsequently with trimethylamine. Working up and purification by column chromatography

- 42 -

yields 0.82 g (29.24% theoretical) of the pure compound, 1-O-octadecyl-3-(1-triazolyl)-3-deoxy-glycero-2-phosphocholine; $R_f=0.20$, silica gel, $CH_2Cl_2/CH_3OH/c.NH_3$ 40/30/6.

5

EXAMPLE 16

By following the procedure of Example 15, except that an equivalent amount each of methylamine and dimethylamine is substituted for the trimethylamine used therein, the respective compounds, 1-O-octadecyl-3-(1-triazolyl)-3-deoxy-glycero-2-phospho- (N-methyl)-ethanolamine and 1-O-octadecyl-3-(1-triazolyl)-3-deoxy-glycero-2-phospho-(N,N-dimethyl)ethanolamine are obtained.

15

EXAMPLE 17

The procedure of Example 15 is followed, except that an equivalent amount of each Formula (J) compound of Example 14 is utilized as the initial reactant, to yield the following respective Formula (K) compounds:

- a. 1-O-tetradecyl-3-(1-imidazolyl)-3-deoxy-glycero-2-phosphocholine;
- b. 1-O-hexadecyl-3-(1-triazolyl)-3-deoxy-glycero-2-phosphocholine;
- 25 c. 1-O-eicosyl-3-pyrrolyl-3-deoxy-glycero-2-phosphocholine;
- d. S-1-O-octadecyl-3-benztriazolyl-3-deoxy-glycero-2-phosphocholine;
- e. R-1-O-hexadecyl-3-indolyl-3-deoxy-glycero-2-phosphocholine;
- 30 f. 1-O-(9-octadecenyl)-3-pyrazolyl-3-deoxy-glycero-2-phosphocholine; and
- g. 1-O-(9-hexadecenyl)-3-(1-triazolyl)-3-deoxy-glycero-2-phosphocholine.

35

EXAMPLE 18

1-Bromo-1-Deoxy-2-O-Octadecyl-3-Benzoyl-Glycerol

- 43 -

8.65 Grams (20 mmol) of 2-O-octadecyl-1,3-benzylidene-glycerol is reacted with 3.92g (22 mmol) of N-bromosuccinimide and 8.90g (40 mmol) of barium carbonate in 100 mL carbon tetrachloride under reflux with stirring for two hours. The reaction mixture is filtered and the filter cake is washed twice with carbon tetrachloride and evaporated to dryness. The residue is taken up in 40 mL of toluene and purified by column chromatography on silica gel with toluene/cyclohexane (3/2) as the mobile phase. Removal of the solvent yields 6.83g (66.70% theoretical) of pure 1-bromo-1-deoxy-2-O-octadecyl-3-benzoyl-glycerol; Rf=0.21, silica gel, toluene.

EXAMPLE 19

The procedure of Example 18 is followed using an equivalent amount of the appropriate Formula (L) compound as the initial reactant to yield the following respective compounds of Formula (M):

- a. 1-bromo-1-deoxy-2-O-tetradecyl-3-benzoyl-glycerol;
- b. 1-bromo-1-deoxy-2-O-hexadecyl-3-benzoyl-glycerol;
- c. 1-bromo-1-deoxy-2-O-eicosyl-3-benzoyl-glycerol; and
- d. 1-bromo-1-deoxy-2-O-(9-octadecenyl)-3-benzoyl-glycerol.

EXAMPLE 20

1-[1-(2-Methyl)-Imidazolyl]-1-Deoxy-2-O-Octadecyl-3-Benzoyl-Glycerol

Ten millimols of 1-bromo-1-deoxy-2-O-octadecyl-3-benzoyl-glycerol is reacted with the Het-Compound, 2-methylimidazole, in accordance with the procedure outlined in Example 3 (Step 2 of Reaction Scheme 1) utilizing the same conditions and molar ratios. After completion of the reaction, workup and purification as therein described, about 2.89 g (56.3% theoretical) of the Formula (N) compound, 1-[1-(2-methyl)-imidazolyl]-1-

- 44 -

deoxy-2-O-octadecyl-3- benzoyl-glycerol, is obtained;
Rf=0.58, silica gel, CH₂Cl₂/CH₃OH 45/5.

EXAMPLE 21

- 5 By following the procedure of Example 20, except that an equivalent amount each of the Formula (M) compound of Example 19 and the appropriate Het-Compound are the reactants, the following respective compounds of Formula (N) are obtained:
- 10 a. 1-(1-triazolyl)-1-deoxy-2-O-octadecyl-3-benzoyl-glycerol;
b. 1-(1-imidazolyl)-1-deoxy-2-O-hexadecyl-3-benzoyl-glycerol;
c. 1-pyrrolyl-1-deoxy-2-O-tetradecyl-3-benzoyl-glycerol;
15 d. 1-benzotriazolyl-1-deoxy-2-O-eicosyl-3-benzoyl-glycerol; and
e. 1-indolyl-1-deoxy-2-O-(9-octadecenyl)-3-benzoyl-glycerol.

EXAMPLE 22

- 20 1-[1-(2-Methyl)-Imidazolyl]-1-Deoxy-2-O-Octadecyl-Glycerol

- Ten millimols of 1-[1-(2-methyl)-imidazolyl]-1-deoxy-2-O- octadecyl-3-benzoyl chloride is debenzoylated
25 in accordance with the procedure outlined in Example 13 (Step 3 of Reaction Scheme 2) utilizing the same conditions and molar ratios to yield about 4.01g of the Formula (O) compound, 1-[1-(2-methyl)-imidazolyl]-1-deoxy-2-O-octadecyl-glycerol; Rf=0.37, silica gel,
30 CH₂Cl₂/CH₃OH 45/5.

EXAMPLE 23

- Debenzoylation of each Formula (N) compound of Example 21 in accordance with the procedure of Example
35 22 affords the following respective compounds of Formula (O):
a. 1-(1-triazolyl)-1-deoxy-2-O-octadecyl-glycerol;

- 45 -

- b. 1-(1-imidazolyl)-1-deoxy-2-O-hexadecyl-glycerol;
- c. 1-pyrrolyl-1-deoxy-2-O-tetradecyl-glycerol;
- d. 1-benztriazolyl-1-deoxy-2-O-eicosyl-glycerol; and
- e. 1-indolyl-1-deoxy-2-O-(9-octadecenyl)-glycerol.

5

EXAMPLE 24

1-[1-(2-Methyl)-Imidazolyl]-1-Deoxy-2-O-Octadecyl-Glycero-3-Phosphocholine

The procedure of Step 4 of Reaction Scheme 1 is followed, reacting 2.04g (5 mmol) of the Formula (O) compound, 1-[1-(2-methyl)-imidazolyl]-1-deoxy-2-O-octadecyl-glycerol, under the same reaction conditions and molar ratios, with 2-chloro-2-oxo-1,3,2-dioxaphospholane and subsequently with trimethylamine. Working up and purification by column chromatography yields 0.79g (27.57 % theoretical) of pure 1-[1-(2-methyl)-imidazolyl]-1-deoxy-2-O-octadecyl-glycero-3-phosphocholine as a colorless, crystalline solid; $R_f=0.15$, silica gel, $CH_2Cl_2/CH_3OH/c.NH_3$ 40/30/6.

20

EXAMPLE 25

By following the procedure of Example 24, except that an equivalent amount each of methylamine and dimethylamine is substituted for the trimethylamine used therein, the respective compounds, 1-[1-(2-methyl)-imidazolyl]-1-deoxy-2-O-octadecyl-glycero-2-phospho-(N-methyl)ethanolamine and 1-[1-(2-methyl)-imidazolyl]-1-deoxy-2-O-octadecyl-glycero-2-phospho-(N,N-dimethyl)-ethanolamine are obtained.

30

EXAMPLE 26

The procedure of Example 24 is followed, except that an equivalent amount of each Formula (O) compound of Example 23 is utilized as the initial reactant, to yield the following respective Formula (P) compounds:

35

- 46 -

- a. 1-(1-triazolyl)-1-deoxy-2-O-octadecyl-glycero-3-phosphocholine;
- b. 1-(1-imidazolyl)-1-deoxy-2-O-hexadecyl-glycero-3-phosphocholine;
- 5 c. 1-pyrrolyl-1-deoxy-2-O-tetradecyl-glycero-3-phosphocholine;
- d. 1-benzotriazolyl-1-deoxy-2-O-eicosyl-glycero-3-phosphocholine; and
- 10 e. 1-indolyl-1-deoxy-2-O-(9-octadecenyl)-glycero-3-phosphocholine.

EXAMPLE 27

2-O-Octadecyl-3-O-Trityl-Glycerol

15 A mixture of 20 g 2-O-octadecylglycerol (58.8 mmol), obtained from conventional acid-catalyzed hydrolysis (HCl / MeOH) of 2-O-octadecyl-1,3-benzylideneglycerol, and 19.6 g triphenylchloromethane (70.56 mmol) in 240 ml of anhydrous pyridine is stirred

20 for 48 h at room temperature under anhydrous conditions. The solution is poured into ice-cold water (500 ml), and the mixture is extracted with 3 portions (200 ml each) of light petroleum. The organic phase is washed with

25 water (3X100 ml) and dried over anhydrous sodium sulphate. The solvent is evaporated, and light petroleum (180 ml) is added to the residue. On standing overnight some triphenylmethanol is precipitated. The solid is filtered off, and the filtrate is evaporated to dryness. The crude product, which contains traces of

30 unreacted 2-O-octadecylglycerol and some 1,3-di-O-trityl-2-O-octadecylglycerol, is purified by column chromatography on silica gel using a petroleum ether-diethylether gradient. The yield of pure 2-O-octadecyl-3-O-trityl-glycerol is 20.5 g (60%).

35

EXAMPLE 28

1-p-Toluenesulfonyl-2-O-Octadecyl-3-O-Trityl-Glycerol

- 47 -

A solution of 2-O-octadecyl-3-O-trityl-glycerol (10 g, 17.04 mmol) in 52 ml water-free pyridine is added dropwise during 30 min. to a solution of p-toulenesulfonyl chloride (5.1 g, 26.75 mmol) in 39 ml water-free pyridine under stirring. After 2 days at room temperature, 162 ml diethyl ether are added and the precipitate formed is removed by filtration. The organic phase is washed successively with water (6X50 ml), 0.5 N HCl (2X29 ml), 0.5 N sodium carbonate (2X29 ml), and water (4X50 ml). Evaporation of the solvent under vacuum gives an oily product which becomes solid after drying in vacuo. The product, 1-p-toluenesulfonyl-2-O-octadecyl-3-O-trityl-glycerol (10.5 g, 85% yield), is used for the next step without further purification.

EXAMPLE 29

1-(1-Imidazolyl)-1-Deoxy-2-O-Octadecyl-3-O-Trityl-Glycerol

The product of Example 28 (10.5 g, 14.1 mmol) and imidazole (2.88 g, 42.3 mmol) are dissolved in water-free dimethyl sulfoxide (80 ml) at 50°C. A solution of sodium dimethylsulfinylmethide, prepared from metallic sodium (0.648 g, 28.2 mg atoms) in 80 ml dimethyl sulfoxide, is added dropwise (over 30 min.) at 50°C. The reaction mixture is stirred at 100°C (silicon oil bath) for 72h. After cooling to room temperature, 210 ml diethyl ether are added and extraction with diethyl ether is repeated with 2X80 ml portions. The ether extracts are combined and washed with water (6X100 ml). The solution is dried over sodium sulfate and the solvent is removed under vacuum. After drying in high vacuum, 8.1 g (90% yield) of crude 1-(1-imidazolyl)-1-deoxy-2-O-octadecyl-3-O-trityl-glycerol are obtained and used in the next step without purification.

- 48 -

EXAMPLE 30

1-(1-Imidazolyl)-1-Deoxy-2-O-Octadecyl-Glycerol

To the product of Example 29 (8.1 g, 12.86 mmol) in 200 ml dichloromethane, borontrifluoride (8 ml; 50% BF₃ in methanol) is added. The dark green solution is stirred at room temperature for 24 h. Then approximately 22 ml 4N NaOH are added to bring the pH to 9.0. The organic phase is washed with water (5X100 ml) and dried over sodium sulfate. Evaporation of the solvent under vacuum gives 8.5 g crude product which is purified by repeated column chromatography on silica gel. First run: column 28X2.8 cm; sequence of solvents:

1. chloroform (100ml);
2. chloroform-methanol-35% ammonia (100: 0.5: 0.25; 201.5 ml);
3. chloroform-methanol-35% ammonia (100:4: 0.25; 104.25 ml); and
4. chloroform-methanol-35% ammonia (100:8:0.25; 433 ml).

Flow rate 12 ml/min., 15 ml fractions are collected and monitored by TLC, using chloroform-methanol (9:1) as the developing solvent. Fractions 22-29 (solvent 4) are combined and the solvents evaporated to yield 3.5 g of product which is chromatographed on a 20X2 cm column, using the same sequence of solvents as for the first chromatography. Fractions 4-29 (solvent 4) are combined and the solvents evaporated to give 2.46 g of 1-(1-imidazolyl)-1-deoxy-2-O-octadecyl-glycerol (50% yield) as a white solid.

EXAMPLE 31

1-(1-Imidazolyl)-2-Deoxy-2-O-Octadecyl-Glycero-3-Phosphocholine

To a solution of 1.1 g of 1-(1-imidazolyl)-1-deoxy-2-O-octadecyl-glycerol (2.78 mmol) and 0.338 g

- 49 -

(0.463 mmol) triethylamine in 28 ml benzene at 6°C is added dropwise (during 30 min.) a solution of 0.476 g (0.31 ml, 3.34 mmol) of 2-chloro-2-oxo-1,3,2-dioxaphospholane in 7 ml benzene. Stirring is continued for 2 h. The precipitate formed is removed by filtration and solvents are evaporated in vacuo to give 2.2 g of solid material, crude compound (V), to which 36 ml acetonitrile are added. The mixture is cooled to -15°C. Then 3.34 g (ca. 5 ml) trimethylamine are added, the reaction flask (500 ml round bottom flask) is sealed with a glass stopper fastened with wire. The mixture is stirred at 60°C for 24h. Evaporation of solvents in vacuo gives 2.2 g of crude 1-(1-imidazolyl)-2-deoxy-2-O-octadecyl-glycero-3-phosphocholine which is purified by column chromatography on silica gel; column 15X1.5 cm; solvents:

1. chloroform-methanol-2N ammonia (85:15:2; 306 ml); and
2. chloroform-methanol-ammonia (80:20:4; 208 ml).

Flow rate 12 ml/min. Fractions (12 ml) are collected and monitored by TLC, using chloroform-methanol-25% ammonia (40:30:6) as the developing solvent. R_f of the product is 0.19. Fractions 17-32 (solvent 2) are combined and give, after evaporation of the solvent, 0.78 g of pure product (50% yield) as a white solid. Identity of the product, 1-(1-imidazolyl)-2-deoxy-2-O-octadecyl-glycero-3-phosphocholine, is confirmed by ¹³C and ¹H NMR.

30

EXAMPLE 32

A. Injection — For 1000 Ampules:

	Ingredients	Amount
	Active Compound	5 g
	Buffering Agents	q.s.
35	Propylene glycol	400 mg
	Water for injection	600 mL

- 50 -

The active compound and buffering agents are dissolved in the propylene glycol at about 50°C. The water for injection is then added with stirring and the resulting solution is filtered, filled into ampules, sealed and sterilized by autoclaving.

B. Capsule — For 1000 Capsules:

	Ingredients	Amount
	Active Compound	50 g
10	Lactose	450 g
	Magnesium stearate	5 g

The ingredients are thoroughly mixed and packed into gelatin capsules.

15 C. Ointment

	Ingredients	Amount
	Active Compound	0.1 - 5%
	Ointment base (white petrolatum and mineral oil)	q.s.

An ointment base consisting of mineral oil and white petrolatum is prepared using relative proportions of each to achieve the desired viscosity. The active compound is added and thoroughly blended to form a homogeneous ointment. For treating psoriasis, an effective amount of a topical corticosteroid, such as 0.05% betamethasone dipropionate or 0.1% triamcinolone acetonide, may also be blended into the ointment.

D. Tablets — For 1000 Tablets:

	Ingredients	Amount
30	Active Compound	50 g

- 51 -

Starch	20 g
--------	------

Magnesium	1 g
-----------	-----

stearate	
----------	--


The active compound and the starch are granulated with water and dried. The magnesium stearate is added
5 to the dried granules and the mixture is thoroughly blended and molded into tablets.

While the invention has been described herein with some specificity, those of skill will recognize
10 variations and modifications of what has been described that are within the spirit of the invention. It is intended that the invention also entails such variations and modifications.

- 52 -

What is claimed is:

1. Heteroaryl substituted
glycero-phosphoethanolamines of the Formulas Ia, Ib and
5 Ic:



and the enantiomeric and cis- and trans-geometric
isomers thereof, wherein the oxygens shown in Figures
Ia, Ib and Ic are oxygens of the glyceryl backbone; R
15 represents a substituted or unsubstituted straight or
branched chain C₁₀₋₂₄ alkyl or alkenyl, said substituent
being one or more of halo, C₁₋₃ alkoxy or cyano, provided
that a double bond of said alkenyl does not involve the
carbon atom of said alkenyl that is bonded to the oxygen
20 of the glyceryl backbone; Het represents a 5- to
9-membered heteroaryl mono- or bicyclic ring system with
1 to 4 nitrogens as the sole heteroatoms, one of which
nitrogens is bonded to the carbon of the glyceryl
backbone; and PEA, together with the oxygen of the
25 glyceryl backbone to which PEA is bonded, represents a
phosphoethanolamine of the formula:



wherein R¹, R² and R³ are each hydrogen or methyl,
provided that at least one of R¹, R² and R³ is methyl; and
the pharmaceutically acceptable salts thereof.

2. A glycerophosphoethanolamine of Claim 1
wherein Het is imidazolyl or 1-triazolyl.

3. A glycerophosphoethanolamine of Claim 1 which
40 is of Formula Ia.

- 53 -

4. A glycerophosphoethanolamine of Claim 1 which is of Formula Ia wherein Het is imidazolyl or 1-triazolyl.

5. A glycerophosphoethanolamine of Claim 1 wherein said R is C₁₄₋₂₀ alkyl or C₁₄₋₂₀ alkenyl.

6. A glycerophosphoethanolamine of Claim 1 wherein said R is C₁₆₋₁₈ alkyl or C₁₆₋₁₈ alkenyl.

10

7. A glycerophosphoethanolamine of Claim 1 wherein R¹, R², and R³ are methyl.

8. A glycerophosphoethanolamine of Claim 1 which is of Formula Ia wherein Het is imidazolyl or 1-triazolyl, R is C₁₆₋₁₈ alkyl, and R¹, R², and R³ are methyl.


9. A compound of Claim 1 which is selected from the group consisting of:

1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine;

1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycero-3-phosphocholine; and

1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine.

10. A method of treating a tumor in a mammal comprising administering to said mammal an anti-tumor-effective amount of a glycerophosphoethanolamine of Formula Ia, Ib or Ic:



or any of the enantiomeric and cis- and trans-geometric isomers thereof, wherein the oxygens shown in Figures Ia, Ib and Ic are oxygens of the glyceryl backbone; R

- 54 -

represents a substituted or unsubstituted straight or branched chain C₁₀₋₂₄ alkyl or alkenyl, said substituent being one or more of halo, C₁₋₃ alkoxy or cyano, provided that a double bond of said alkenyl does not involve the carbon atom of said alkenyl that is bonded to the oxygen of the glyceryl backbone; Het represents a 5- to 9-membered heteroaryl mono- or bicyclic ring system with 1 to 4 nitrogens as the sole heteroatoms, one of which nitrogens is bonded to the carbon of the glyceryl backbone; and PEA, together with the oxygen of the glyceryl backbone to which PEA is bonded, represents a phosphoethanolamine of the formula:



wherein R¹, R² and R³ are each hydrogen or methyl, provided that at least one of R¹, R² and R³ is methyl; or a pharmaceutically acceptable salt thereof.

11. The method of Claim 10 wherein said glycerophosphoethanolamine is a compound of Formula Ia.


12. The method of Claim 10 wherein said glycerophosphoethanolamine is a compound of Formula Ia in which Het is imidazolyl or 1-triazolyl, R is C₁₆₋₁₈ alkyl, and R¹, R² and R³ are methyl.

13. The method of Claim 10 wherein said glycerophosphoethanolamine is selected from the group consisting of:

- 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine;
- 1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycero-3-phosphocholine; and
- 1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine.

- 55 -

14. The method of treating psoriasis in a mammal comprising administering to said mammal an anti-psoriatic-effective amount of a glycerophosphoethanolamine of Formula Ia, Ib or Ic:



or any of the enantiomeric and cis- and trans-geometric isomers thereof, wherein the oxygens shown in Figures Ia, Ib and Ic are oxygens of the glyceryl backbone; R represents a substituted or unsubstituted straight or branched chain C₁₀₋₂₄ alkyl or alkenyl, said substituent being one or more of halo, C₁₋₃ alkoxy or cyano, provided that a double bond of said alkenyl does not involve the carbon atom of said alkenyl that is bonded to the oxygen of the glyceryl backbone; Het represents a 5- to 9-membered heteroaryl mono- or bicyclic ring system with 1 to 4 nitrogens as the sole heteroatoms, one of which nitrogens is bonded to the carbon of the glyceryl backbone; and PEA, together with the oxygen of the glyceryl backbone to which PEA is bonded, represents a phosphoethanolamine of the formula:



wherein R¹, R² and R³ are each hydrogen or methyl, provided that at least one of R¹, R² and R³ is methyl; or a pharmaceutically acceptable salt thereof.

15. The method of Claim 14 wherein said glycerophosphoethanolamine is a compound of Formula Ia.

- 56 -

16. The method of Claim 14 wherein said glycerophosphoethanolamine is a compound of Formula Ia in which Het is imidazolyl or 1-triazolyl, R is C₁₆₋₁₈ alkyl, and R¹, R² and R³ are methyl.


5

17. The method of Claim 14 wherein said glycerophosphoethanolamine is selected from the group consisting of:

1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycerophosphocholine;
 1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycerophosphocholine; and
 1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycerophosphocholine.

15

18. The method of treating inflammation in a mammal comprising administering to said mammal an anti-inflammatory-effective amount of a glycerophosphoethanolamine of Formula Ia, Ib or Ic:



or any of the enantiomeric and cis- and trans-geometric isomers thereof, wherein the oxygens shown in Figures Ia, Ib and Ic are oxygens of the glyceryl backbone; R represents a substituted or unsubstituted straight or branched chain C₁₀₋₂₄ alkyl or alkenyl, said substituent being one or more of halo, C₁₋₃ alkoxy or cyano, provided that a double bond of said alkenyl does not involve the carbon atom of said alkenyl that is bonded to the oxygen of the glyceryl backbone; Het represents a 5- to 9-membered heteroaryl mono- or bicyclic ring system with 1 to 4 nitrogens as the sole heteroatoms, one of which nitrogens is bonded to the carbon of the glyceryl backbone; and PEA, together with the oxygen of the

35

- 57 -

glyceryl backbone to which PEA is bonded, represents a phosphoethanolamine of the formula:



wherein R¹, R² and R³ are each hydrogen or methyl, provided that at least one of R¹, R² and R³ is methyl; or a pharmaceutically acceptable salt thereof.


19. The method of Claim 18 wherein said glycerophosphoethanolamine is a compound of Formula Ia.

20. The method of Claim 18 wherein said glycerophosphoethanolamine is a compound of Formula Ia in which Het is imidazolyl or 1-triazolyl, R is C₁₆₋₁₈ alkyl, and R¹, R² and R³ are methyl.

21. The method of Claim 18 wherein said glycerophosphoethanolamine is selected from the group consisting of:


1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine;
1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycero-3-phosphocholine; and
1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycero-3-phosphocholine.

22. A pharmaceutical composition comprising an anti-tumor-, anti-psoriatic- or anti-inflammation-effective amount of a heteroaryl substituted glycerophosphoethanolamine of Formulas Ia, Ib or Ic:



- 58 -

or any of the enantiomeric and cis- and trans-geometric isomers thereof, wherein the oxygens shown in Figures Ia, Ib and Ic are oxygens of the glyceryl backbone; R represents a substituted or unsubstituted straight or branched chain C₁₀₋₂₄ alkyl or alkenyl, said substituent
 5 being one or more of halo, C₁₋₃ alkoxy or cyano, provided that a double bond of said alkenyl does not involve the carbon atom of said alkenyl that is bonded to the oxygen of the glyceryl backbone; Het represents a 5- to
 10 9-membered heteroaryl mono- or bicyclic ring system with 1 to 4 nitrogens as the sole heteroatoms, one of which nitrogens is bonded to the carbon of the glyceryl backbone; and PEA, together with the oxygen of the glyceryl backbone to which PEA is bonded, represents a
 15 phosphoethanolamine of the formula:



20 wherein R¹, R² and R³ are each hydrogen or methyl, provided that at least one of R¹, R² and R³ is methyl; or a pharmaceutically acceptable salt thereof.

25 23. The composition of Claim 22 wherein Het is imidazolyl or 1-triazolyl.

24. The composition of Claim 22 wherein said glycerophosphoethanolamine is a compound of Formula Ia.

30 25. The composition of Claim 22 wherein R is selected from the group consisting of C₁₄₋₂₀ alkyl and C₁₄₋₂₀ alkenyl.

35 26. The composition of Claim 22 wherein R is selected from the group consisting of C₁₆₋₁₈ alkyl and C₁₆₋₁₈ alkenyl.

- 59 -

27. The composition of Claim 22 wherein said glycerophosphoethanolamine is a compound of Formula Ia wherein Het is imidazolyl or 1-triazolyl, R is C₁₆₋₁₈ alkyl, and R¹, R² and R³ are methyl.

5

28. The composition of Claim 22 wherein said glycerophosphoethanolamine is selected from the group consisting of:

10 1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycerophosphocholine;
1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycerophosphocholine; and
1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycerophosphocholine.

15

29. A pharmaceutical composition for topical use comprising from about 0.1 to about 5.0 weight percent of a compound of Claim 1 and a pharmaceutically acceptable carrier in ointment form.

20

30. The topical composition of Claim 29 wherein said compound is a compound of Formula Ia wherein Het is imidazolyl or 1-triazolyl, R is C₁₆₋₁₈ alkyl, and R¹, R² and R³ are methyl.


25

31. The topical composition of Claim 29 wherein said compound is selected from the group consisting of:
1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycerophosphocholine;
30 1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycerophosphocholine; and
1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycerophosphocholine.

35

- 60 -

32. Heteroaryl-substituted glycerols of the Formulas IIa, IIb and IIc:



and the enantiomeric and cis- and trans-geometric isomers thereof, wherein the oxygens shown in Figures IIa, IIb and IIc are oxygens of the glyceryl backbone; R represents a substituted or unsubstituted straight or branched chain C_{10-24} alkyl or alkenyl, said substituent being one or more of halo, C_{1-3} alkoxy or cyano, provided that a double bond of said alkenyl does not involve the carbon atom of said alkenyl that is bonded to the oxygen of the glyceryl backbone; Het represents a 5- to 9-membered heteroaryl mono- or bicyclic ring system with 1 to 4 nitrogens as the sole heteroatom, one of which nitrogens is bonded to the carbon of the glyceryl backbone; and the salts thereof.

33. A compound of Claim 32 wherein Het is imidazolyl or 1-triazolyl.

34. A compound of Claim 32 which is of Formula IIa.

35. A compound of Claim 32 wherein R is selected from the group consisting of C_{14-20} alkyl and C_{14-20} alkenyl.

36. A compound of Claim 32 wherein R is selected from the group consisting of C_{16-18} alkyl and C_{16-18} alkenyl.

37. A compound of Claim 32 which is of Formula IIa wherein Het is imidazolyl or 1-triazolyl and R is C_{16-18} alkyl.

- 61 -

38. The compound of Claim 32 which is selected from the group consisting of:

1-O-octadecyl-2-(1-imidazolyl)-2-deoxy-glycerol;

1-O-octadecyl-2-(1-triazolyl)-2-deoxy-glycerol; and

5 1-O-hexadecyl-2-(1-imidazolyl)-2-deoxy-glycerol.




FIGURE 1FIGURE 2FIGURE 3

Figure 4
CPR-1006

CPR-1006

**National Cancer Institute Developmental Therapeutics Program
Mean Graphs**

Mean Graphs






FIGURE 7FIGURE 8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/16034

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.
US CL : 514/93,94; 548/112, 119
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : C07D 233/54, 233/58; A61K 31/41
514/93,94; 548/112, 119

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	US, A, 5,405,841 (MAURER ET AL.) 11 April 1995, see entire document.	1-38

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 MARCH 1996

Date of mailing of the international search report

09 APR 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOSEPH K. MCKANE aco

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/16034

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07D 233/54, 233/58
A61K 31/41